AAMU
XLRN

Amundi Asset Management US’s Acceleron Pharma XLRN Stock Holding History

Amundi Asset Management US’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,600
Closed -$244K – 1691
2019
Q4 		$244K Hold
4,600
– – ﹤0.01% 1427
2019
Q3 		$182K Sell
4,600
-10,558
-70% -$458K ﹤0.01% 1481
2019
Q2 		$623K Sell
15,158
-23,868
-61% -$988K ﹤0.01% 1328
2019
Q1 		$1.82M Buy
39,026
+35,426
+984% +$1.56M ﹤0.01% 1107
2018
Q4 		$157 Buy
+3,600
New +$180K ﹤0.01% 1428

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Amundi Asset Management US's XLRN Position: Q1 2020 in Review

Amundi Asset Management US sold out of Acceleron Pharma (XLRN) in Q1 2020, closing a stake of 4,600 shares — an estimated $244K sold.

Amundi Asset Management US first reported a position in XLRN in Q4 2018 and held it in 5 quarters. The position peaked at $1.82M in Q1 2019. 217 funds tracked by Wall St. Rank hold XLRN as of Q1 2020.

  • Amundi Asset Management US reported no remaining Acceleron Pharma position as of Q1 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 4,600 Acceleron Pharma shares in Q1 2020, an estimated $244K.
  • Amundi Asset Management US first reported a position in Acceleron Pharma in Q4 2018 and held it in 5 quarters.
  • Amundi Asset Management US's Acceleron Pharma position peaked at $1.82M in Q1 2019.
  • 217 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2020.

Based on Amundi Asset Management US's 13F filing for Q1 2020, filed 15 May 2020.